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Abstract
Background: Intra-articular injection of tranexamic acid (TXA) is known to be effective in controlling blood loss
after total knee arthroplasty (TKA). However, this method has some disadvantages, such as TXA leakage due to soft
tissue release. Peri-articular injection provides an alternative to intra-articular administration of TXA. This study aimed
to evaluate the effects of peri-articular injection of TXA in reducing blood loss after TKA and compare them to those of
intra-articular TXA injection.
Methods: This was a retrospective analysis of 127 patients who underwent primary, unilateral TKA for knee osteoarthritis
in our hospital between January 2014 and December 2014. Cases were classified into 3 comparison groups: 49 patients
in the peri-articular TXA group, 36 in the intra-articular group, and 42 in the control group (TXA not administered).
Demographic variables, hemoglobin (Hb) measured before and after surgery, operation time, total amount of drained
volume, time of removing drains, units of blood transfused peri- and postoperatively, estimated volume of blood loss,
and preoperative comorbidities were retrieved from the patients’ medical charts. Statistical analyses were performed
using SPSS 19.0 software.
Results: There were no significant differences of demographic variables and operation time among three groups
(P > 0.05). Compared to the control group, both TXA groups had a significantly reduced volume of blood loss,
postoperative knee joint drainage, hemoglobin concentration, time of removing drains, and need for blood
transfusion (P < 0.05). The effects of TXA were comparable for the two methods of injection (P > 0.05). There
were no deep venous thrombosis or thromboembolic complications in any group.
Conclusions: Peri-articular injection of TXA is as effective as an intra-articular injection in reducing postoperative
blood loss during TKA. Both methods had a statistically significant benefit in reducing the change in Hb concentration,
volume of joint drainage, and estimated volume of blood loss when compared to the control group. Peri-articular
injection of TXA can significantly reduce the blood transfusion rate compared to the control group.
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Background
Major postoperative blood loss is one of the most com-
mon problems associated with total knee arthroplasty
(TKA). Postoperative blood loss can range between
1000 mL and 2000 mL [1, 2], with 10–38 % of patients
requiring transfusion of 1–2 units of blood [1–4]. Blood
transfusions implicitly lead to the risk for infection, graft-
versus-host disease, hemolysis, and transfusion-related
acute lung injury [5]. In addition, blood products are ex-
pensive and in short supply. Therefore, controlling blood
loss associated with TKA is an important clinical issue.
Several methods have been introduced to reduce TKA-
associated blood loss. The administration of tranexamic
acid (TXA), an antifibrinolytic agent, is currently a “hot
topic” of research. Several studies have reported that intra-
venous (IV) administration of TXA significantly reduces
postoperative blood loss and the need for transfusion [4, 6].
However, several medical conditions, most notably a history
of deep venous thrombosis (DVT), cerebrovascular and
cardiac disease, and renal failure, are commonly identified
as comorbidities in patients undergoing TKA; they affect
the use of IV-TXA. In addition, only a small percentage of
the TXA solution administered by IV reaches the target
location and tissue [7]. To address these clinical limitations,
TXA has increasingly been administered via intra-articular
injection (IAI) after TKA [7–12].
The safety and efficacy of IAI of TXA has been dem-
onstrated in several studies [7–12]. However, the re-
ported effectiveness of this method has been questioned.
In particular, the volume of intra-articular TXA solu-
tion, usually reported to be 5–25 mL in previous stud-
ies [7, 13, 14], may be insufficient to immerse the
anterior tissues of the knee joint when the patient is
placed in a supine position during surgery. In addition, ex-
tensive soft tissue release, which is required in some cases
to balance forces on the knee, may cause the injected
TXA solution to leak from the joint.
A peri-articular injection (PAI), in which the TXA so-
lution is injected into the soft tissue around the joint
cavity before closure, is an alternative to an IAI of TXA.
PAI also has the distinct advantage of allowing the sur-
geon to target areas that are vulnerable to postoperative
bleeding, such as sites of soft tissue release and incisal
edges in the synovial membrane. Therefore, our aim was
to conduct a retrospective analysis of patients who
underwent TKA at our hospital and were administered
either IAI-TXA or PAI-TXA to evaluate the effectiveness
of these two modes of TXA administration in control-
ling postoperative blood loss compared to patients who
did not receive TXA.
Methods
TXA has been used in TKA surgeries in our hospital since
May 2014. Between May 2014 and September 2014, we
used an IAI of TXA in TKA as previously reported [4, 15].
However, we observed leakage of the TXA solution in
some cases, especially in those who needed severe soft tis-
sue release, and we switched to PAI of TXA in the
followed TKA cases. Between January 2014 and December
2014, we retrospectively reviewed medical charts to iden-
tify patients between the ages of 50 and 80 years and in
whom TKA was performed as a treatment for dege-
nerative arthritis. Preoperative comorbidities that were
thought to influence either bleeding tendency or thrombo-
embolic tendency were recorded, as well as use of anti-
coagulant drugs such as warfarin and clopidogrel. All
anticoagulant drugs were stopped prior to surgery, and
coagulation system data were repeated and found to be
normal on admission. After the retrospective review of
TKA cases, 127 subjects were identified (23 male and 104
female). Of these 127 cases, 49 (8 male and 41 female) re-
ceived PAI-TXA, forming the PAI-TXA group; 36 (5 male
and 31 female) received IAI-TXA, forming the IAI-TXA
group; and 42 patients (10 male and 32 female) were not
administered TXA, forming the control group.
All surgeries were performed under general anesthesia
by the same surgeon, who was a specialist in TKA
procedures. A pneumatic tourniquet was prepared as a
precautionary measure in case of emergent situations,
such as injury to an artery, but not inflated during the
surgery in those cases. A midline skin incision was
made, followed by a medial para-patellar capsular ap-
proach, to expose the surgical site of the knee joint.
Intra-operative hemostasis was applied in standard fash-
ion. After bone resection of the distal femur and prox-
imal tibia, the soft tissue balancing was performed, and
the appropriate type and size of knee prosthesis compo-
nents were cemented, polyethylene liners were inserted,
and the patella was resurfaced. An intra-articular drain
was placed in situ, followed by wound closure. For peri-
articular administration of TXA, the TXA solution was
injected into the soft tissues around the joint cavity, 5 to
10 mL at each point, such as posterior joint capsulae
synovial membrane and ligaments, especially the sites of
soft tissue release and incisal edges in the synovial mem-
brane, before the proximal and distal components of the
prosthesis were implanted. For the intra-articular admin-
istration of TXA, the TXA solution was injected into the
knee joint cavity after wound closure, with the drain
clamped for 15 min to allow for absorption of the TXA,
and then released.
The doses of TXA were comparable to concentrations
reported in previous studies of IV-TXA in TKA, show-
ing positive effects with doses of 15 to 20 mg/kg [4, 15]
and concentrations of 10–100 mg/mL for topical TXA
solutions [7, 9, 14, 16]. Therefore, doses of 2 g of TXA
in 80 mL normal saline were used for PAI and IAI. The
contraindications of use of TXA were patients with an
Mao et al. BMC Musculoskeletal Disorders  (2016) 17:438 Page 2 of 8
allergy to TXA, an actual infection, any type of cancer,
atrial fibrillation and angina, stroke, rheumatoid arthritis,
and revision TKA.
Postoperatively, drains were removed when the 24-h
volume of drainage was less than 50 mL. Hemoglobin
(Hb) was measured preoperatively and at 12 h, 24 h, and
48 h postoperatively. The change in Hb was the differ-
ence between the lowest level preoperatively and postop-
eratively. All patients were administered a standard
course of daily oral anticoagulant (Rivaroxaban; Xarelto,
Bayer Schering Pharma AG, Germany) for two weeks,
starting on the first postoperative day. Patients were ex-
amined daily for clinical symptoms of DVT during the
hospital stay and for 6 weeks postoperatively. Doppler
ultrasonography examination was applied when there was
a clinical suspicion of DVT. Once Doppler confirmed
DVT, therapeutic low molecular weight heparin was ad-
ministered. In addition, all patients received rehabilitation
exercises that included a passive knee flexibility exercise
and quadriceps femoris contraction exercise before drain
removal, and the patients were allowed to walk with a
walker after removal of the drain. The patients were usu-
ally discharged 14 days after surgery, unless there were
wound complications. Patients had regular follow up every
month for the first six months and yearly thereafter.
Demographic and clinical variables were retrieved from
the patients’ medical charts and included: age, sex, height,
weight, body mass index, Hb measured before and after
surgery to quantify change in Hb concentration preopera-
tive platelet blood test, preoperative coagulation system
data (international normalized ratio, prothrombin time,
activated partial thromboplastin time), operation time,
total amount of drained volume, time of removing drains,
units of blood transfused peri- and postoperatively, and
preoperative comorbidities. The volume of blood loss was
estimated using a previously reported method [4]. The cri-
terion for blood transfusion was an Hb level < 8 g/dL or a
postoperative Hb level between 8 and 10 g/dL with clinical
signs of hemodynamic instability; this criterion was con-
sistent with the Guidelines of the American Society of
Anesthesiologists [17]. We evaluated the range of motion
(ROM) to determine patients’ functional outcomes at
follow-up. The ROM was measured with a universal goni-
ometer that is commonly used in clinical practice [18, 19].
Statistical analyses were performed using SPSS 19.0
software. Continuous variables were expressed as a
mean ± standard deviation. Between-group differences
for demographic and clinical variables were evaluated
using one-way analysis of variance, and a least squared
difference post-hoc test was used for variables with
homogeneity of variance or Dunnett’s test was used for
variables with heterogeneity of variance. Between-group
differences in the distribution of men and women in
each group and the number of transfusions were ana-
lyzed with cross-tabulation. A value of P < 0.05 was
considered to be statistically significant.
Results
The demographic variables for our study group are listed
in Table 1, with no significant between-group differences
among the three experimental groups. The postoperative
volume of knee joint drainage is reported in Fig. 1. The
volume was significantly lower for patients in the PAI-
TXA and IAI-TXA groups compared to the control group
Table 1 The demographic data of the subjects in this study
PAI TXA group (n = 49) IAI TXA group (n = 36) Control group (n = 42) P value
Age (years) 68.5 ± 7.4 69.7 ± 7.2 69.6 ± 5.7 0.66
Gender (M/F) 8/41 5/31 10/32 0.48
Height (m) 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 0.49
Weight (kg) 67.6 ± 11.7 65.1 ± 10.4 67.9 ± 9.3 0.44
BMI (kg/cm2) 25.9 ± 3.7 25.6 ± 3.9 26.6 ± 3.8 0.47
Preoperative Hb (g/L) 124.3 ± 10.5 123.8 ± 10.7 125.9 ± 12.9 0.69
INR 0.98 ± 0.2 0.95 ± 0.1 0.94 ± 0.0 0.38
PT (s) 11.5 ± 2.5 11.1 ± 0.7 11.1 ± 0.6 0.33
APTT (s) 27.0 ± 4.3 27.0 ± 3.3 27.0 ± 2.9 0.99
PLT (×109/L) 213.7 ± 77.8 212.1 ± 63.5 212.8 ± 61.1 0.99
Operation time (min) 94.5 ± 16.4 92.1 ± 13.3 88.5 ± 10.3 0.12
Anticoagulant use, % yes 8.2 11.1 9.5 0.90
Thromboembolic tendency, % yes 14.3 11.1 14.3 0.89
Coagulopathies, % yes 2 0 0 0.20
Values are expressed as the mean ± standard deviation
PAI TXA peri-articular injection of tranexamic acid, IAI TXA intra-articular injection of tranexamic acid, BMI body mass index, Hb hemoglobin, INR international nor-
malized ratio, PT prothrombin, APTT activated partial thromboplastin time, PLT platelet
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(P < 0.05), with a mean volume of 324.9 ± 189.4 mL for
the PAI-TXA group, 305.0 ± 169.1 mL for the IAI-TXA
group, and 724.1 ± 288.4 mL for the control group. The
volume of drainage was comparable for the two TXA
groups (P = 0.94). The times of removing drains were 36.6
± 12.0 h for the PAI-TXA group, 42.6 ± 13.0 h for the IAI-
TXA group, and 63.8 ± 13.6 h for the control group. The
times of removal were comparable for the two TXA
groups (P = 0.13), but were both significantly shorter than
that of the control group (P < 0.05).
The mean change in Hb concentration was signifi-
cantly lower for both TXA groups compared to the con-
trol group (P < 0.05), with a mean reduction of the Hb
concentration of 23.2 ± 9.3 g/L in the PAI-TXA group,
24.3 ± 10.0 g/L in the IAI-TXA group, and 33.3 ± 14.4 g/L
in the control group. The amount of change in Hb
concentration was comparable for the PAI-TXA and IAI-
TXA groups (P = 0.67) (Fig. 2).
The estimated volume of blood loss was significantly
lower for patients in the PAI-TXA group (872.8 ± 333.3 mL)
and IAI-TXA group (914.2 ± 469.4 mL) compared to
patients in the control group (1487.1 ± 975.7 mL) (P < 0.05).
Again, there was no significant difference between the two
TXA groups (P = 0.96) (Fig. 3).
The number of patients requiring blood transfusions is
reported in Table 2. The rate of blood transfusion was
comparable for both TXA groups (P = 0.71), with 8
patients receiving a transfusion in the PAI-TXA group
and 7 patients receiving a transfusion in the IAI-TXA
group. In comparison, 16 patients required a blood
transfusion in the control group, a transfusion rate that
was significantly higher than in the PAI-TXA group, but
not significantly different compared to the IAI-TXA
group (P = 0.07) (Table 2).
We divided the patients who did and did not use anti-
coagulants into three groups to investigate whether the
Fig. 1 The postoperative drainage volume of the three groups.
Legend: The volume was significantly lower for patients in the
PAI-TXA and IAI-TXA groups compared to the control group
(P < 0.05) and was comparable for the two TXA groups (P = 0.94)
Fig. 2 The mean change in Hb concentration before and after
surgery of the three groups. Legend: The mean change in Hb
concentration was significantly lower for both TXA groups compared
to the control group (P < 0.05), and had no significant difference
between the PAI-TXA and IAI-TXA groups (P = 0.67)
Fig. 3 The estimated volume of blood loss of the three
groups.Legend: The estimated volume of blood loss was significantly
lower for patients in the PAI-TXA and IAI-TXA group compared to
those in the control group (P < 0.05). There was no significant differ-
ence between the two TXA groups (P = 0.96)
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anticoagulation usage would impact the volume of knee
joint drainage, drop in Hb, and estimated blood loss
after TKA (Table 3). We found that there was no signifi-
cant difference between the patients who did and did
not use anticoagulation therapy in the PAI, IAI, and con-
trol groups (P > 0.05). The results were comparable be-
tween patients who did not use anticoagulation therapy
in the PAI and IAI groups (P > 0.05). However, there was
a significant difference between these patients and those
who did not use anticoagulants in the control group.
There was no significant difference among the three
subgroups when anticoagulation was used (P > 0.05)
(Table 3).
There was no DVT or thromboembolic complication
in any group. No surgical site or wound complications
occurred. All patients had satisfactory ROM results after
surgery. At the first three-month follow-up visit, no sig-
nificant difference was found among the three groups
(P > 0.05) (Table 4). At this follow-up visit, patients’
ROM reached 120°.
Discussion
The main findings of the current study were that PAI of
TXA is as effective as IAI of TXA in reducing postoperative
blood loss during TKA. Both methods had a statistically
significant benefit in reducing the change in Hb concentra-
tion, volume of joint drainage, and estimated volume of
blood loss when compared to a control group.
TXA is a well-known antifibrinolytic agent used to de-
crease blood loss in various surgical and other medical cir-
cumstances, such as in the management of craniocerebral
trauma, postpartum hemorrhage, hemophilia hemorrha-
ging, and menorrhea [20–23]. Recently, IV and topical
intra-operative administration of TXA have been reported
to reduce postoperative blood loss and the consequent
need for blood transfusion after TKA [6, 10, 24]. Several
meta-analysis have provided evidence that IV administra-
tion of TXA does not increase the risk for DVT [25, 26];
however, Raveendran et al.[27] considered that the effects
of TXA on thromboembolic events and mortality remain
uncertain. Therefore, topical administration of TXA has
been considered a safe alternative to IV administration,
limiting the systemic absorption of TXA while providing
the benefit of directly increasing drug activity at the
application site. Wong et al.[8] found that the plasma
levels detected in patients using topical TXA were signifi-
cantly less than in patients receiving an equivalent IV-
administered dose.
Topical TXA has become the routine form of care since
Seo et al.[16] reported their findings of the effectiveness of
Table 2 The number of patients requiring blood transfusions in the three groups
Groups Number of Patients
with Transfusions (%)
P Value (Compared to
PAI TXA Group)
P Value (Compared to
IAI TXA Group)
P Value (Compared to
Control Group)
PAI TXA Group (n = 49) 8 (16.32) N/A 0.71 0.02
IAI TXA Group (n = 36) 7 (19.44) 0.71 N/A 0.07
Control Group (n = 42) 16 (38.10) 0.02 0.07 N/A
PAI TXA peri-articular injection of tranexamic acid, IAI TXA intra-articular injection of tranexamic acid
Table 3 Subgroup analysis of patients on anticoagulants
Anticoagulation use
or not




P value P* P**












Values are expressed as a mean ± standard deviation
PAI peri-articular injection, IAI intra-articular injection, U anticoagulation used, N anticoagulation not used
P*: Differences (Three groups, PAI-N vs. IAI-N, PAI-N vs. Control-N, IAI-N vs. Control-N) among subgroups of PAI-N, IAI-N, and Control-N
P**: Differences (three groups, PAI-U vs. IAI-U, PAI-U vs. Control-U, IAI-U vs. Control-U) among subgroups of PAI-U, IAI-U, and Control-U
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intra-articular administration of TXA in reducing the
volume of blood loss and transfusion rate, compared to
IV administration. After surgical hemostasis is achieved,
a topical application of TXA can reduce topical fibrin-
olysis and consequently stabilize clot formation and
promote microvascular hemostasis, thereby decreasing
bleeding [28, 29].
In the majority of studies evaluating the clinical bene-
fits of topical use of TXA, the application method has
been an IAI [9–12]. However, the following limitations
of IAI of TXA have been noted. In some studies, the vol-
ume of intra-articular TXA solution applied ranged only
from 5 mL to 25 mL [7, 13, 14]. This low volume of so-
lution may not be sufficient to immerse all soft tissues of
the knee joint effectively, particularly when the patient is
placed in the supine position for surgery. This would
compromise the effectiveness of TXA in controlling
bleeding at the sites near the anterior aspect of the knee
joint. In addition, in some cases of advanced knee osteo-
arthritis, extensive soft tissue release is required to achieve
soft tissue balance. Such extensive soft release would allow
leakage of intra-articular TXA into surrounding tissues. A
PAI of TXA, in contrast, would improve permeation of
TXA into the deeper soft tissues of the knee joint and
avoid TXA leakage. Furthermore, a peri-articular method
of administration allows selective application of TXA to
potential sites of bleeding, such as released soft tissues
and the incisal margin areas in synovial membrane.
Finally, a PAI simplifies postoperative management of the
patient by eliminating the need to clamp the drain, as re-
quired with intra-articular administration.
Postoperative anemia increases the risk for postopera-
tive complications, including wound complications, poor
functional recovery, and a longer hospital stay due to the
potential need for blood transfusion [3]. In our study,
PAI of TXA was effective in lowering the volume of
postoperative blood loss and blood transfusion in pa-
tients undergoing primary unilateral TKA. PAI-TXA also
reduced the volume of postoperative joint drainage,
leading to an earlier removal of the drain. The volume of
postoperative drainage of 324.9 ± 189.4 mL in patients in
the PAI-TXA group, within 48 h, was similar to volumes
of 297 ± 196 mL reported by Alshryda et al. (intra-ar-
ticular) [9] and 401 ± 82.4 mL reported by Roy et al.
(intra-articular) [14]. In addition, the effectiveness of
PAI-TXA in reducing the volume of postoperative blood
loss and preserving Hb concentrations in our study is
consistent and comparable with the findings of previous
studies reported by Georgiadis et al. (intra-articular) [6],
Wong et al. (intra-articular) [8], and Aguilera et al.
(intravenous) [30].
The method for topical administration of TXA, how-
ever, has remained a controversial issue in clinical prac-
tice. Maniar et al.[15] evaluated five different methods of
TXA administration, reporting that an IAI, compared to
no intervention, reduced the volume of blood loss but
had no discernible effects on postoperative joint drain-
age volume. Sarzaeem et al.[31] compared IV adminis-
tration of TXA to two topical methods, IAI and peri-
articular irrigation (not injection), to a control group.
Among the TXA groups, IAI of TXA led to less blood loss
compared to IV administration, and IV administration led
to less blood loss than irrigation of the knee joint with
TXA. In our study, we found that both PAI and IAI of
TXA significantly reduced the blood loss and wound
drainage after TKA compared to the control group.
TXA is a synthetic analog of the amino acid lysine, and
it serves as an antifibrinolytic. Although few adverse ef-
fects have been reported in the orthopedic field, concerns
about thromboembolism persist. Many studies show that
IV or IAI of TXA during TKA was not associated with a
significant incidence of DVT [7, 8, 14, 16]. In the current
study, no DVT or thromboembolic complication was
found, confirming the results of those studies.
Anticoagulant drugs may influence bleeding. In our
study, we divided each group into two subgroups, the
anticoagulation not used subgroup and the anticoagula-
tion used subgroup, in order to investigate the impact of
anticoagulation use on the volume of knee joint drain-
age, drop in Hb, and estimated blood loss. There was no
significant difference among the three anticoagulation
used subgroups (P > 0.05), which were inconsistent with
the results among the three groups; this may be attrib-
uted to the small sample size of these three subgroups,
which only had 4 patients each. Further well-designed
studies may be needed to understand if anticoagulant
drug use would influence the therapeutic effect of TXA.
The limitations of our study need to be acknowledged.
Foremost, as a retrospective study with a relatively small
sample size, the level of evidence is low. In addition, we
did not measure systemic blood levels of TXA and,
therefore, the level of TXA leaked from the soft tissue
and joint space of the knee into the systemic circulation
could not be determined. Furthermore, avoiding TXA
leakage is thought to be a theoretical advantage of the
PAI method. In our experience, no TXA leakage oc-
curred using this method. Due to our small sample size,
further well-designed randomized controlled trials will
Table 4 Follow-up ROM of the patients in the three groups
One month Two months Three months
PAI TXA Group (n = 49) 97.8 ± 5.8 110.6 ± 5.2 124.0 ± 4.3
IAI TXA Group (n = 36) 96.5 ± 5.1 109.6 ± 4.4 125.4 ± 4.1
Control Group (n = 42) 96.9 ± 5.2 108.5 ± 7.4 125.0 ± 4.0
P value 0.53 0.22 0.29
Values are expressed as a mean ± standard deviation
ROM range of motion, PAI TXA peri-articular injection of tranexamic acid,
IAI TXA intra-articular injection of tranexamic acid
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be required to investigate if avoiding TXA leakage is an
actual advantage of the PAI method compared to the
IAI method,
Conclusions
The peri-articular injection of TXA is as effective as the
intra-articular injection in reducing postoperative blood
loss in TKA, while possessing several potential advantages.
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